TABLE 2.
Meta‐analysis studies of postoperative outcomes in patients with CD treated with vedolizumab (VDZ)
| Authors | Type of complication | No. studies included | Study population | Control | Vedo group complication rate (%) | Control group complication rate (%) | OR (CI) |
|---|---|---|---|---|---|---|---|
| Guo et al 100 |
Any complication Infectious All SSI |
2 2 2 |
143 360 569 |
Non‐vedolizumab | Not reported | Not reported |
2.09 (0.36–12.02) 0.40 (0.14–0.94) 2.97 (1.75–5.02) |
| Guo et al 100 |
All SSI ileus |
2 3 |
343 343 |
Anti‐TNF‐α agents |
Not reported | Not reported |
3.69 (1.69–8.08) 2.46 (1.16–5.22) |
| Guo et al 100 |
All SSI Ileus |
2 2 |
366 366 |
Non‐biological agents | Not reported | Not reported |
2.47 (1.21–5.04) 2.40 (1.14–5.07) |
| Yung et al 101 |
All complication Infectious SSIs Major |
2 2 2 2 |
343 343 343 343 |
Anti‐TNF‐α agents |
40/140 (29) 33/140 (24) 27/140 (19) 13/140 (9) |
41/203 (20) 24/203 (12) 18/203 (9) 12/203 (6) |
1.45 (0.31–6.86) 1.00 (0.07–13.86) 1.16 (0.08–17.38) 1.16 (0.10–13.90) |
| Yung et al 101 |
All complications Infectious SSIs Major |
2 2 2 2 |
366 366 366 366 |
Non‐biological agents |
40/140 (29) 33/140 (24) 27/140 (19) 13/140 (9) |
55/226 (24) 30/226 (13) 25/226 (11) 19/226 (8) |
1.24 (0.21–7.52) 0.84 (0.04–15.88) 0.91 (0.07–11.58) 0.84 (0.18–3.91) |
| Law et al 91 | Infectious | 4 | Not reported | Not reported | Not reported | Not reported | 1.32 (0.51–3.42) |